scholarly journals Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye

2002 ◽  
Vol 86 (2) ◽  
pp. 181-184 ◽  
Author(s):  
P. Aragona
Keyword(s):  
Dry Eye ◽  
Ocular Surface ◽  
Sodium Hyaluronate ◽  
Surface Damage ◽  
Term Treatment ◽  
Artificial Tears ◽  
Long Term Treatment

scholarly journals Mucoadhesive Bletilla striata Polysaccharide-Based Artificial Tears to Relieve Symptoms and Inflammation in Rabbit with Dry Eyes Syndrome

Polymers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1465 ◽  
Author(s):  
Minal Thacker ◽  
Ching-Li Tseng ◽  
Chih-Yen Chang ◽  
Subhaini Jakfar ◽  
Hsuan Yu Chen ◽  
...  
Keyword(s):  
Physical Properties ◽  
Dry Eye ◽  
Ocular Surface ◽  
Close Association ◽  
Term Treatment ◽  
Artificial Tears ◽  
Dry Eyes ◽  
Bletilla Striata ◽  
Long Term Treatment ◽  
Anti Inflammatory

Dry eye syndrome (DES) is a multifactorial disorder of the ocular surface affecting many people all over the world. However, there have been many therapeutic advancements for the treatment of DES, substantial long-term treatment remains a challenge. Natural plant-based polysaccharides have gained much importance in the field of tissue engineering for their excellent biocompatibility and unique physical properties. In this study, polysaccharides from a Chinese ground orchid, Bletilla striata, were successfully extracted and incorporated into the artificial tears for DES treatment due to its anti-inflammatory and mucoadhesive properties. The examination for physical properties such as refractive index, pH, viscosity and osmolality of the Bletilla striata polysaccharide (BSP) artificial tears fabricated in this study showed that it was in close association with that of the natural human tears. The reactive oxygen species (ROS) level and inflammatory gene expression tested in human corneal epithelium cells (HCECs) indicated that the low BSP concentrations (0.01–0.1% v/v) could effectively reduce inflammatory cytokines (TNF, IL8) and ROS levels in HCECs, respectively. Longer retention of the BSP-formulated artificial tears on the ocular surface is due to the mucoadhesive nature of BSP allowing lasting lubrication. Additionally, a rabbit’s DES model was created to evaluate the effect of BSP for treating dry eye. Schirmer test results exhibited the effectiveness of 0.1% (v/v) BSP-containing artificial tears in enhancing the tear volume in DES rabbits. This work combines the effectiveness of artificial tears and anti-inflammatory herb extract (BSP) to moisturize ocular surface and to relieve the inflammatory condition in DES rabbit, which further shows great potential of BSP in treating ocular surface diseases like DES in clinics in the future.

Ocular Surface Alteration after Long-term Treatment with an Antiglaucomatous Drug

Ophthalmology ◽  
1992 ◽  
Vol 99 (7) ◽  
pp. 1082-1088 ◽  
Author(s):  
José M. Herreras ◽  
J. Carlos Pastor ◽  
Margarita Calonge ◽  
Victor M. Asensio
Keyword(s):  
Ocular Surface ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Surface Alteration

scholarly journals Diquafosol zur Behandlung der Keratokonjunktivitis sicca: 12-Monats-Ergebnisse einer prospektiven Studie

2021 ◽  
pp. 1-2
Author(s):  
Björn Bachmann
Keyword(s):  
Dry Eye ◽  
Real World ◽  
Tear Film ◽  
Ophthalmic Solution ◽  
Term Treatment ◽  
Summary Score ◽  
Open Label ◽  
Staining Score ◽  
Long Term Treatment

<b>Introduction:</b> Diquafosol is a P2Y<sub>2</sub> receptor agonist that has been shown to be effective in the treatment of dry eye disease (DED) in short-term studies; however, its long-term safety and effectiveness have not been evaluated in a real-world setting. <b>Methods:</b> This prospective, multicentre, open-label observational study was conducted in patients with DED over 12 months. Safety endpoints included the incidence of adverse drug reactions (ADRs) and serious ADRs. Effectiveness endpoints included change from baseline in keratoconjunctival staining score, tear film break-up time (BUT) and Dry Eye-related Quality of Life Score (DEQS). <b>Results:</b> A total of 580 patients were included, most of whom were female (82.9%). The proportion of patients who completed 12 months of observation was 55.0%, the most common reason for discontinuation was patient decision (54.6%). The incidence of ADRs was 10.7% and was highest during the first month of treatment (5.5%); no serious ADRs were reported. Compared with baseline, significant improvements in all effectiveness outcomes, including keratoconjunctival fluorescein staining score, BUT and DEQS summary score, were observed at each evaluation during the treatment period (p &#x3c; 0.001). <b>Conclusion:</b> The present, real-world study showed that diquafosol 3.0% ophthalmic solution was well tolerated and effective in the long-term treatment of DED.

scholarly journals Outcomes of Sjögren’s versus non-Sjögren’s related dry eye in a longitudinal, tertiary clinic-based sample

PLoS ONE ◽  
2021 ◽  
Vol 16 (12) ◽  
pp. e0261241
Author(s):  
David Cui ◽  
Priya Mathews ◽  
Gavin Li ◽  
Shanna VanCourt ◽  
Esen Akpek
Keyword(s):  
Dry Eye ◽  
Term Treatment ◽  
Final Visit ◽  
Complication Rates ◽  
Staining Score ◽  
Long Term Treatment ◽  
Surface Staining ◽  
Corneal Staining

Purpose To assess the long-term treatment outcomes of dry eye in patients with and without underlying primary Sjögren’s syndrome (SS). Design Retrospective longitudinal cohort. Methods SS and non-SS dry eye patients with clinic visits for a minimum of 5 consecutive years at a tertiary, dedicated dry eye clinic were included. Electronic health records were reviewed to collect data regarding demographics, objective dry eye parameters, treatments utilized at baseline and final visit, and corneal complications observed during follow-up. Results Two hundred and two patients (101 SS and 101 randomly selected non-SS), with a mean follow-up of 7.1 years were included. At baseline, mean conjunctival lissamine green staining score was 2.9 and mean corneal fluorescein staining score was 2.0. At last visit, notable improvement in staining score for cornea (–1.1, P < .001) and conjunctiva (–1.8, P < .001) was seen equally in both dry eye groups. Most patients (88.1%) had an escalation of treatment by the final visit, with similar rates in both groups (P = .51). Half (48.9%) of the patients had no conjunctival staining, and a third (34.4%) had no corneal staining at their last visit. Twenty (9.9%) patients experienced a vision-threatening corneal complication, including ulcers and melt, with no difference in occurrences between the groups (P = .64). Conclusions The majority of patients in this longitudinal, tertiary clinic-based sample demonstrated improvement in their ocular surface staining score by the final visit with escalation in treatment. Treatments used, improvement achieved, and corneal complication rates leading to loss of vision were similar in both SS and non-SS dry eye groups.

scholarly journals Our Experience Olopatadine Treatment of Allergic Conjunctivitis in Children

2021 ◽  
Vol 18 (2) ◽  
pp. 361-367
Author(s):  
T. N. Vorontsova ◽  
M. V. Zaitseva ◽  
M. A. Chramtsova
Keyword(s):  
Dry Eye ◽  
Allergic Conjunctivitis ◽  
Tear Film ◽  
Term Treatment ◽  
Dry Eye Syndrome ◽  
Chronic Type ◽  
Film Stability ◽  
Lissamine Green ◽  
Long Term Treatment

The authors analyzed the treatment results of 53 patients (106 eyes) with allergic conjunctivitis. All patients received Olopatadine 0.2 % (Visallergol) in drops once a day during 1 month. All patients underwent the same tests: scraping from the conjunctiva for the presence of eosinophils, evaluation of the inflammation symptoms using 4-ball scale, biomicroscopy of cornea and conjunctiva with staining by lissamine green and tear film stability (Norn’s method). All of the above-mentioned tests were performed before the treatment, on 14-th day and after the course of therapy. The inflammatory reaction of conjunctiva, the amount of discharge in the conjunctival cavity and the staining of the conjunctiva with lissamine green decreased in all patients starting from the 14-th day of treatment. The maximal effectiveness of the drop was registered in patients with the chronic type of allergic conjunctivitis. The manifestation of the disease reduced significantly after 1 month of treatment, but it does not disappear completely. So it is necessary to continue therapy after 1 month. The laboratory methods of diagnosis confirm the effectiveness of Visallergol by disappearance of eosinophils in the conjunctiva scrapings. The secondary dry eye syndrome developed in all types of the allergic conjunctivitis and needs a long-term treatment. The maximal intensity of dry eye syndrome was registered in patients with chronic type of the allergic conjunctivitis. The drop can be used starting from 2 years old. 

Hypnotherapy is effective in the long-term treatment of functional dyspepsia

2001 ◽  
Vol 120 (5) ◽  
pp. A115-A115 ◽  
Author(s):  
E CALVERT ◽  
L HOUGHTON ◽  
P COOPER ◽  
P WHORWELL
Keyword(s):  
Functional Dyspepsia ◽  
Term Treatment ◽  
Long Term Treatment

1608: Long-Term Treatment with High Doses of Sildenafil Does Not Up-Regulate the Levels of Phosphodiesterase 5 (Pde5) in the Rat Penis

2004 ◽  
Vol 171 (4S) ◽  
pp. 424-424 ◽  
Author(s):  
Monica G. Ferrini ◽  
Eliane G. Valente ◽  
Jacob Rajfer ◽  
Nestor F. Gonzalez-Cadavid
Keyword(s):  
Term Treatment ◽  
Long Term Treatment ◽  
High Doses ◽  
Phosphodiesterase 5
Sign in / Sign up

Export Citation Format

Share Document